Sexual Health

CytoDyn submits first part of biologics license application to FDA for flagship HIV drug leronlimab

By
1 Mins read
77
0
Share
Reading Time: < 1 minute

A researcher in a lab

CytoDyn Inc (OTCMKTS:CYDY), a Vancouver-based biotech announced Monday that it has filed the non-clinical portion of a Biologics License Application for its flagship leronlimab (PRO 140) as a combination therapy for HIV using the US Food and Drug Administration (FDA)’s rolling review process.  Read More

77
0
Share
Related posts
Sexual Health

Revealed: The nation where you could be most likely to catch an STI...so who comes out on top?

By
1 Mins read
Reading Time: < 1 minute They are the third most commonly used form of contraception in the UK, behind the Pill and the hormonal implant, official data…
Sexual Health

Gonorrhoea could become 'untreatable' as cases of the STI reach record level

By
1 Mins read
Reading Time: < 1 minute An increasing number of people catching the sexually transmitted infection are finding it does not respond to antibiotics.  Read More
Sexual Health

The impact of HIV/AIDS and STIs on fertility: What Indian couples need to know

By
1 Mins read
Reading Time: < 1 minute Sexually transmitted infections (STIs) and reproductive tract infections (RTIs) are major global health issues, impacting quality of life, causing infertility, cancers, and…
Subscribe to our Blog

Let's stay in touch. Subscribe to our blog and get our best content in your inbox. 

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.